Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting

Phase 2

Completed

• Conditions: Diabetes Mellitus, Type 1
• Interventions: Drug: 27-hour inpatient intervention

• Registration Number: NCT03800875
• Lead Sponsor: McGill University

Brief Summary

Closed-loop system systems that are shown to alleviate the burden of carbohydrate counting without degrading glucose control are still lacking. In this proposal, the investigators aim to develop a novel, fully-automated, closed-loop system that delivers insulin and pramlintide that controls postprandial glucose levels without any input from the user.

Detailed Description

Meal carbohydrate content is the main determinant of prandial insulin needs, and consequently, accurate carbohydrate counting is recommended for type 1 diabetes. Advances in glucose sensors have motivated the development of the closed-loop system to automatically regulate glucose levels in individuals with type 1 diabetes. In the closed-loop system, a dosing algorithm adjusts the pump insulin infusion rate based on continuous glucose sensor readings.

Closed-loop system systems that are shown to alleviate the burden of carbohydrate counting without degrading glucose control are still lacking. In this proposal, the investigators aim to develop a novel, fully-automated, closed-loop system that delivers insulin and pramlintide that controls postprandial glucose levels without any input from the user. Thus, the two hormones' role in the postprandial state will be as follows:

1. Insulin: to reduce plasma glucose levels. Insulin delivery needs to be aggressive to counter-act fast increase in post-meal glucose levels.

2. Pramlintide: to slow gastric emptying and aim insulin in efficiently controlling postprandial glucose levels.

The aim of this study is to assess a fully automated, dual-hormone, closed-loop system that delivers insulin, and pramlintide to control glucose levels without degrading overall glycemic control compared to an insulin-alone closed-loop system with carbohydrate-matched boluses.

The investigators hypothesize that the dual-hormone closed-loop system will alleviate carbohydrate-counting burden (fully reactive system) without degrading glucose control compared to the insulin-alone closed-loop system.

Study Timeline

• Study First Submitted: 2018-06-27
• Study First Submitted QC: 2019-01-10
• Study First Posted: 2019-01-11
• Study Start: 2019-02-08
• Primary Completion: 2020-09-19
• Study Completion: 2020-09-19
• Status Verified: 2021-06
• Last Update Submitted: 2021-06-03
• Last Update Posted: 2021-06-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Males and females ≥ 18 years of age.
2. Clinical diagnosis of type 1 diabetes for at least 12 months. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.
3. Insulin pump therapy for at least 6 months.
4. HbA1c ≤ 12% in the last 6 months.

Exclusion Criteria

1. Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2, GLP-1, Metformin, Acarbose, etc....).
2. Severe hypoglycemic episode within one month of admission.
3. Severe diabetic ketoacidosis episode within one month of admission.
4. Pregnancy.
5. Known or suspected allergy to the study drugs.
6. Gastroparesis.
7. Use of prokinetic drugs that stimulate gastric emptying (domperidone, cisapride, metoclopramide).
8. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.
9. Recent (< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
10. Current use of glucocorticoid medication.
11. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
12. Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc.).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Insulin-Pramlintide Closed-Loop Strategy	27-hour inpatient intervention	Fast-acting insulin will be delivered using two separate infusion pumps. The pumps' infusion rates will then be changed manually based on the computer-generated recommendation. The computer-generated recommendations are based on a dosing algorithm. With no-meal announcement or carbohydrate counting, the dual-hormone closed-loop system will be fully reactive, and insulin and pramlintide dosages will be based solely on sensor readings
Insulin-alone Closed Loop Strategy	27-hour inpatient intervention	Fast-acting insulin will be delivered by a subcutaneous insulin infusion pump based on an algorithm that automatically adjusts insulin rates based on a dosing algorithm. The carbohydrate content for every ingested meal will be entered into the algorithm to calculate the insulin prandial bolus based on each participant's insulin-to-carbohydrate ratio. The carbohydrate content will be entered at the onset of the meal. Drug(s): Insulin (FiAsp)

Primary Outcome Measures

Name	Time	Method
Total percentage of time (22:00-22:00) that the glucose concentration remained within 3.9 and 10.0 mmol/L	24 hours

Secondary Outcome Measures

Name	Time	Method
The number and severity of gastrointestinal sysmptoms experienced by a participant	27 hours	GI symptoms include: nausea, vomiting, bloating and heartburn
Mean glucose level	24-hour period
Total amount of insulin delivered to the participant	24 hours
Mean sensor glucose concentration during the overnight stay	8 hours
Number of participants experiencing hypoglycemia requiring oral treatment during: a. the overall study period; b. the night; c. the day	27 hours
Mean daytime concentration of amylin	14 hours
Total percentage of time (22:00-22:00) that the glucose concentration remained within specified ranges.	24 hours	a. between 3.9 and 7.8 mmol/L; b. below 3.9 mmol/L; c. between 3.9 and 10 mmol/L d. below 3.3 mmol/L; e. below 2.8 mmol/L; f. above 7.8 mmol/L; g. above 10 mmol/L; h. above 13.9 mmol/L; i. above 16.7 mmol/L.
Percentage of overnight time (24:00-8:00) that the glucose concentration remained within specified ranges.	8 hours	a. between 3.9 and 7.8 mmol/L; b. between 3.9 and 10 mmol/L; c. below 3.9 mmol/L; d. below 3.3 mmol/L; e. below 2.8 mmol/L; f. above 7.8 mmol/L; g. above 10 mmol/L; h. above 13.9 mmol/L; i. above 16.7 mmol/L.
Mean daytime insulin concentration	14 hours
Total amount of pramlintide delivered to the participant	24 hours

Trial Locations

Locations (1)

McGill University Health Centre; 🇨🇦 Montréal, Quebec, Canada